Targeting the sarcoplasmic reticulum Ca-ATPase (SERCA2a) pump is being investigated as a potential therapeutic strategy for heart failure in both preclinical and clinical studies.
content for the next contraction. However, decreased SERCA2a expression and/or pump activity are key features in HF. As a result, there is a growing interest in developing therapeutic approaches to target SERCA2a. This review provides an overview of the regulatory mechanisms of the SERCA2a pump and explores potential strategies for SERCA2a-targeted therapy, which are being investigated in both preclinical and clinical studies.
Changwon Kho (Tue,) conducted a review in Heart failure. SERCA2a-targeted therapy was evaluated. Targeting the sarcoplasmic reticulum Ca-ATPase (SERCA2a) pump is being investigated as a potential therapeutic strategy for heart failure in both preclinical and clinical studies.